Kim Chung-Jong, Bae Ji-Yun, Jun Kang-Il, Kim Jihee, Son Hee-Jung, Chung Hae-Sun, Kim Soo-Kyung, Kim Soohyun, Minn Dohsik, Choi Hee-Jung
Department of Internal Medicine, Ewha Womans University Seoul Hospital, Seoul 07804, Korea.
Ewha Education and Research Center for Infection, Seoul 07985, Korea.
Vaccines (Basel). 2022 Oct 26;10(11):1797. doi: 10.3390/vaccines10111797.
This study aimed to investigate the efficacy of different COVID-19 booster vaccines by measuring the serum antibody titer. SARS-CoV-2 anti-nucleocapsid protein antibody (N-Ab), anti-spike protein antibody (S-Ab), and neutralizing antibody (Neut.Ab) were measured before and 4-6 weeks after booster vaccinations in healthcare personnel with a previous vaccination within 3-6 months. Personnel who previously received two doses of ChAdOx1 vaccine or two doses of BNT162b2 vaccine received the BNT162b2 vaccine (AAP and PPP groups, respectively). Personnel who previously received two doses of mRNA-1273 received the same vaccine as a booster dose (MMM group). Of the 917 participants, the AAP, MMM, and PPP groups comprised 837 (91.3%), 27 (2.9%), and 53 (5.8%) participants, respectively. The pre-booster S-Ab and Neut.Ab titer were significantly lower in the AAP group. After the booster vaccination, all participants were positive for S-Ab and Neut.Ab; furthermore, the S-Ab and Neut.Ab titer significantly increased in all three groups, although the post-booster S-Ab was lower in the AAP group than in the other groups. The post-booster Neut.Ab titer showed no significant difference among the groups. Our study's results suggest that booster vaccination, after two prior vaccinations, shows a significant effect regardless of the type of vaccine administered.
本研究旨在通过测量血清抗体滴度来调查不同新冠病毒加强疫苗的效力。在3至6个月内曾接种过疫苗的医护人员中，于加强疫苗接种前及接种后4至6周测量了严重急性呼吸综合征冠状病毒2（SARS-CoV-2）抗核衣壳蛋白抗体（N-Ab）、抗刺突蛋白抗体（S-Ab）和中和抗体（Neut.Ab）。先前接种过两剂ChAdOx1疫苗或两剂BNT162b2疫苗的人员分别接种BNT162b2疫苗（分别为AAP组和PPP组）。先前接种过两剂mRNA-1273的人员接种相同疫苗作为加强剂量（MMM组）。在917名参与者中，AAP组、MMM组和PPP组分别有837名（91.3%）、27名（2.9%）和53名（5.8%）参与者。加强疫苗接种前，AAP组的S-Ab和Neut.Ab滴度显著较低。加强疫苗接种后，所有参与者的S-Ab和Neut.Ab均呈阳性；此外，尽管加强疫苗接种后AAP组的S-Ab低于其他组，但三组的S-Ab和Neut.Ab滴度均显著升高。加强疫苗接种后的Neut.Ab滴度在各组之间无显著差异。我们研究的结果表明，在先前接种两剂疫苗后进行加强疫苗接种，无论接种的疫苗类型如何，均显示出显著效果。
